Skip to Page Content
Home  |  Contact Us  |  Press Room  |  Site Overview  |  Help  |  Login  |  Register
Add to MyNCSL

PHARMACEUTICALS: Overview and NCSL Resources

Updated: June 25, 2008

State Rx Legislation

Breaking/Recent NewsNew item

NCSL On-Line Reports

Non-NCSL Resources

Pharmaceutical Statistics

News Archives

AT A GLANCE: Prescription drugs continue as one of the most active health policy issues for 2008.  NCSL has followed the state aspects of these issues for a number of years.

Prescription drug spending is projected to reach $497.5 billion by 2016, more than double the expected drug spending level for 2006. CMS researchers predicted that prescription drug spending will grow at an average annual rate of 8.6 percent until 2016, as increases in the generic drug dispensing rate levels off, new drugs to treat cancer and other diseases are approved, and drugs already on the market gain approval for new versions or treatments. Drug spending in 2006 was expected to grow 6.5 percent.  Implementation of Part D has increased prescription drug use among beneficiaries who previously had limited or no drug coverage. However, the expected increase as a result of Part D is anticipated to be offset by a deceleration in drug price growth.  (CMS Office of the Actuary, release 2/21/2007).

  • In 2006, 63 percent of all prescription drugs dispensed in the United States were generics -- a 13 percent increase from 2005.  That is due in part to patent expirations for several brand-name drugs. (Center for Medicine in the Public Interest, October 2007)
  • Spending on anti-depressants, anti-psychotic drugs, drugs to reduce cardiovascular risk, treat pain and insomnia was $127 billion in 2005 and was nearly two-thirds of the total $199 billion spent on all outpatient prescription medicines (Agency for Healthcare Research and Quality, February 2008)
    • $36 billion for prescription drugs to lower blood sugar, reduce cholesterol, or treat other metabolic problems.
    • $33 billion for drugs to reduce high blood pressure and treat heart conditions.
    • $26 billion for central nervous system drugs, including pain killers, sleep aids and attention-deficit disorder drugs.
    • Anti-depressants and anti-psychotic drugs cost $17 billion,
    • gastrointestinal drugs, including antacids and laxatives, cost consumers $15 billion.

As of Spring 2008, at least 38 states had passed some type of state pharmaceutical assistance law and four others had executive agency initiatives, for a total of 42 states with assistance programs enacted or authorized. Most use state funds to help pay for a portion of the cost of pharmaceuticals for eligible residents who meet age and income criteria. Some states also have established cost-sharing features including co-payments, annual enrollment fees, or monthly limits.

Other states are operating or authorizing broader discount programs aimed at assisting people lacking private insurance, or even the general consuming public. In separate actions, all 50 states have adjusted Medicaid pharmaceutical policy in the past six years. NCSL now has more than 70 reports and presentations on pharmaceuticals, most of which are online and listed below.

RECENT MATERIALS & ACTIVITY:

Upcoming NCSL session on Pharmaceuticals: New item
IDEAS AT ORK FOR PRESCRIPTION DRUGS
Wednesday, July 23, from 1 pm-2:30 pm.  - Meeting Details and Registration

 NCSL Legislative Summit

 Hear about three programs that are up and running in a growing number of states.

  1. Prescription Drug Monitoring Programs help medical professionals prevent misuse and abusers from obtaining prescriptions fraudulently before the police knock on the door.
    > Speaker: Sherry Green, National Alliance for Model State Drug Laws, Alexandria, VA.
  2. The federal 340B Drug Pricing Program helps over 12,400 qualified health centers, clinics and hospitals provide comprehensive pharmacy services for over 10 million patients.
    > Speaker: Lisa Scholz, HRSA Pharmacy Services Support Center, Washington, DC.
  3. Medication Therapy Management (MTM) programs allow pharmacists to provide in-depth counseling to insure that patients get the full benefit of chronic prescribed drugs.
    > NCPA spokesperson.
    > Marjorie Powell, Senior Assistant General Counsel, PhRMA, Washington, DC.


NCSL ON-LINE REPORTS & PRESENTATIONS:

These web documents include information on laws and initiatives to provide state subsidies, as well as discounts, bulk purchasing, price regulation and other regulatory and funding policies, including state Medicaid and Medicare activities:

MMA- MEDICARE MODERNIZATION ACT:

More NCSL Reports 2003-2005

Non-NCSL Resources:   

Prescription Drug Resources for 2007 - A selection of additional reports from government, academic, industry and consumer sources, including 50+ direct web links, updated regularly. Note:  NCSL provides links to other Web sites for information purposes only.  Providing these links does not indicate NCSL's support or endorsement of the site.

NCSL Archive Reports:

(Items three or more years old that may still be of interest)

Go to NCSL Health menu page

Denver Office: Tel: 303-364-7700 | Fax: 303-364-7800 | 7700 East First Place | Denver, CO 80230 | Map
Washington Office: Tel: 202-624-5400 | Fax: 202-737-1069 | 444 North Capitol Street, N.W., Suite 515 | Washington, D.C. 20001